Kevin V.McCarthy

Associate

纽约 + 1.212.326.3441

联系：

Share

Kevin McCarthy focuses his intellectual property practice on patent litigation before the district courts, the Federal Circuit, and the Patent Trial and Appeal Board (PTAB). He represents leading pharmaceutical, telecommunications, and industrial gas clients enforcing their intellectual property rights through Hatch-Waxman and other patent infringement actions, inventorship disputes, and inter partes review (IPR) proceedings. Kevin's litigation experience includes pre-suit investigations, discovery, motion practice, claim construction, pretrial proceedings, and appeals.

Prior to joining Jones Day, Kevin worked as a research chemist at Sterling Lacquer Mfg. Co., where he was responsible for polyurethane coatings development for the commercial and military aerospace industries.

经验

  • Purdue Pharma defends petition for post-grant review of patent against Collegium Pharmaceutical Inc.Jones Day represented patent owner Purdue Pharma L.P. in a post-grant review (PGR) proceeding brought by petitioner Collegium Pharmaceutical Inc. relating to a patent directed to a pharmaceutical formulation containing gelling agent.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Accord HealthcareJones Day represents plaintiffs Purdue Pharma L.P. and Purdue Pharmaceuticals L.P. ("Purdue") in a patent litigation under the Hatch-Waxman Act in the District of Delaware.
  • Tineco prevails in ITC patent infringement dispute with Bissell over wet-dry surface cleaning devicesJones Day successfully represented Tineco Intelligent Technology Co., Ltd. as respondent in an ITC Section 337 investigation filed by complainants Bissell Inc. and Bissell Homecare Inc. ("Bissell") relating to wet-dry surface cleaning devices.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to extended-release oxycodone analgesic productsJones Day represents plaintiffs Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and Rhodes Technologies in a Hatch-Waxman pharmaceutical patent litigation in the District of New Jersey.
  • R.J. Reynolds successfully enforces patents in ITC trial against Philip Morris in dispute over cigarette alternativeJones Day's client Reynolds achieved a precedent-setting victory before the International Trade Commission (ITC) against its main competitors Philip Morris Products S.A. ("Philip Morris") and Altria Client Services LLC ("Altria") in a patent infringement dispute involving tobacco heating and vaping products.
  • Purdue enforces formulation and compound patents against Collegium Pharmaceutical's Xtampza® ER extended-release oxycodone capsulesJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against Collegium Pharmaceutical, Inc., relating to Collegium's submission of a Section 505(b)(2) application for its Xtampza® ER extended-release oxycodone capsules.
  • Sloan Kettering and Juno Therapeutics win over $1.1 billion after jury verdict and post-trial motions in patent dispute with Kite Pharma/Gilead involving CAR-T therapyOn behalf of patentee Sloan Kettering Institute and exclusive licensee Juno Therapeutics (a subsidiary of Celgene Corporation, a Bristol Myers Squibb company), Jones Day and co-counsel prevailed in a jury trial that spanned eight days and involved 22 witnesses, wherein the jury awarded our clients $752 million in compensation for the infringement of their patents by Kite Pharma, Inc. (a Gilead Sciences, Inc. company) through the making and selling of its infringing CAR-T therapy, YESCARTA®.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against IntellipharmaceuticsJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of a Section 505(b)(2) New Drug Application to the FDA seeking approval of an extended-release oxycodone formulation.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Ascent related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendant Ascent Pharmaceuticals, Inc., pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of OxyContin®.
  • Purdue Pharma successfully moves for additional discovery regarding real-party-in-interest, leading to termination of IPRs before institutionJones Day defended patent owner, Purdue Pharma L.P., in connection with two inter partes review (IPR) petitions brought by the petitioner, Kashiv Pharma, LLC, against U.S. Patent Nos. 9,492,392 and 9,492,393.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Epic Pharma related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Epic Pharma, LLC and PuraCap Pharmaceutical LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of OxyContin®.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Amneal and Kashiv related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Amneal Pharmaceuticals, LLC and Kashiv Pharma, LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Major Japanese electronics manufacturer defends patent infringement claims involving mobile handsetsJones Day is defending a Japanese electronics manufacturer against allegations by Koninklijke KPN N.V. that certain mobile handsets infringe KPN's U.S. Patent No. 6,212,662, entitled Method and Devices for the Transmission of Data with Transmission Error Checking.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against MylanJones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®Jones Day client Purdue Pharma L.P. successfully resolved a patent infringement action it brought under the Hatch-Waxman Act against two companies that sought FDA approval to market a generic version of Purdue's Butrans® product prior to the expiration of certain patents owned by Purdue.
  • Major Japanese electronics manufacturer defends patent infringement claims involving softwareJones Day is defending a Japanese electronics manufacturer against allegations by Uniloc USA, Inc. that certain software infringes Uniloc's U.S. Patent No. 8,571,194, entitled System and Method for Initiating a Conference Call.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against KVK-Tech and AbhaiJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Purdue Pharma defends against claims of patent infringementJones Day represents Purdue Pharma L.P., The P.F. Laboratories, Inc., and Purdue Pharmaceuticals L.P. in a patent infringement litigation brought by plaintiff Depomed, Inc., based on Purdue's manufacture and sale of its own patented controlled-release OxyContin(R) pain relief medication.
    •

    December 2024 Blog

    The “Best Way” to Avoid Adverse Judgment

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice